Last updated on November 2019

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Brief description of study

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blinded treatment (either etrasimod 2 mg per day or placebo) during participation in one of two Phase 3 double-blinded, placebo-controlled studies (either Study APD334-301 or APD334-302).

Clinical Study Identifier: NCT03950232

Find a site near you

Start Over

San Diego Gastroenterology Medical Associates

San Diego, CA United States
  Connect »